Washington, DC 20006-5349
HELPLINE
In an analysis published last week, the Centers for Disease Control and Prevention (CDC) reported a significant increase in mesothelioma deaths among women during the…
This week, the paper “Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations,” by Drs. Michele Carbone, Harvey Pass, and…
Data from a study comparing the efficacy of anetumab ravtansine, a monoclonal antibody conjugate, against vinorelbine showed no improvement in progression-free survival. The results of…
The Meso Foundation has joined together with hundreds of other rare disease advocacy organizations as part of Rare Disease Week 2022.Julie Powers, Meso Foundation Executive…
The field of radiology and imaging has relatively quickly advanced from simple x-rays that allow us to take a non-invasive, albeit limited, peek inside the…
As 2021 concludes and 2022 begins, we bring you mesothelioma treatment news directly from clinicians and researchers. Two newly published articles give us a useful…
This week, Nature Medicine published the results, as well the genomic and immunologic analyses, from the Phase 2 PrE0505 clinical trial. The trial, which took…
Thanks to the generous support of our patients, families, caregivers, corporate supporters, and the many friends of the Mesothelioma Applied Research Foundation, we are pleased…
Jessica Blackford-Cleeton and Rich Mosca, both members of the mesothelioma community, recently participated in the evaluation of research proposals for funding through the Congressionally Directed…
Today, Bristol Myers Squibb announced new three-year overall survival data from its CheckMate -743 study. These data are based on the clinical trial of nivolumab/ipilimumab…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
